What is the 13F Pro Quality Score for GH?

13F Pro ranks Guardant Health, Inc. (GH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GH's current score at https://13fpro.ai/research/GH (free sign-up required for the full ranking).

Where does 13F Pro source GH data?

All Guardant Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Guardant Health, Inc. files with the SEC under CIK 1576280. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GH in?

Guardant Health, Inc. (GH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GH research updated on 13F Pro?

GH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Guardant Health, Inc.(GH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1576280 GH stock profile & AI dashboard →

13F Pro Quality Score

36.1/100

Rank #2,112 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

88.2/100

Profitability

12.6/100

Balance Sheet

11.6/100

Earnings Quality

30.0/100

Free Cash Flow

12.7/100

Institutional Flow

56.6/100

Revenue Scale

49.6/100

Dilution Risk

11.2/100

GH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Guardant Health, Inc. (GH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GH at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,112 of 2,879 stocks — the bottom half of the AI-ranked universe. GH scores in the top quartile across revenue growth (88.2). Areas of concern include balance sheet strength (11.6) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Guardant Health, Inc. reports quarterly revenue of $301.7M, net income of $-112.1M, an operating margin of -40.2%. Top institutional holders of GH by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GH trades on the Nasdaq exchange and files with the SEC under CIK 1576280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardant Health, Inc. directly from SEC EDGAR. Guardant Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 65 since 2021, currently 36.1 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$301.7M

Net Income

Q1 2026

$-112.1M

Free Cash Flow

Q1 2026

$-71.2M

Operating Margin

Q1 2026

-40.2%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+32.9% YoY

$982.0MFY 2025

FY22 $449.5MFY23 $563.9MFY24 $739.0MFY25 $982.0M

Net Income

+4.6% YoY

$-416.3MFY 2025

FY22 $-654.6MFY23 $-479.4MFY24 $-436.4MFY25 $-416.3M

Operating Income

+1.4% YoY

$-437.2MFY 2025

FY22 $-544.4MFY23 $-564.7MFY24 $-443.6MFY25 $-437.2M

EPS (Diluted)

+6.7% YoY

$-3.32FY 2025

FY22 $-6.41FY23 $-4.28FY24 $-3.56FY25 $-3.32

Total Assets

+35.5% YoY

$2.01BFY 2025

FY22 $1.61BFY23 $1.79BFY24 $1.49BFY25 $2.01B

Total Debt

+31.6% YoY

$1.50BFY 2025

FY22 —FY23 —FY24 $1.14BFY25 $1.50B

Op. Cash Flow

+23.0% YoY

$-184.8MFY 2025

FY22 $-309.5MFY23 $-325.0MFY24 $-239.9MFY25 $-184.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$982.0M +32.9%	$739.0M +31.0%	$563.9M +25.5%	$449.5M +20.3%	$373.7M +74.3%	$214.4M
Net Income	$-416.3M +4.6%	$-436.4M +9.0%	$-479.4M +26.8%	$-654.6M -70.1%	$-384.8M -408.7%	$-75.7M
Operating Income	$-437.2M +1.4%	$-443.6M +21.4%	$-564.7M -3.7%	$-544.4M -32.5%	$-411.0M -399.0%	$-82.4M
EPS (Diluted)	$-3.32 +6.7%	$-3.56 +16.8%	$-4.28 +33.2%	$-6.41 -60.3%	$-4.00 -376.2%	$-0.84
Total Assets	$2.01B +35.5%	$1.49B -16.8%	$1.79B +11.0%	$1.61B -27.0%	$2.20B +129.0%	$962.5M
Total Debt	$1.50B +31.6%	$1.14B	—	—	—	—
Operating Cash Flow	$-184.8M +23.0%	$-239.9M +26.2%	$-325.0M -5.0%	$-309.5M -48.1%	$-209.0M -343.5%	$-47.1M

AI Insight: GH Ratio Trends

Guardant Health shows meaningful margin improvement with operating losses narrowing from -62.4% in Q4 2024 to -40.2% in Q1 2026.

• Operating margin improved 22.2pp from Q4 2024 trough of -62.4% to -40.2% in Q1 2026.

• Net profit margin recovered from -55.0% in Q4 2024 to -37.1% in Q1 2026.

• ROA improved from -29.9% in Q4 2024 to -23.4% in Q1 2026, showing asset efficiency gains.

• ROIC remains deeply negative at -36.7% despite improvement from -52.5% trough in Q2 2025.

⚠ Operating margin deteriorated sequentially from -37.3% in Q3 2025 to -40.2% in Q1 2026.

⚠ Company remains unprofitable across all metrics with no clear path to breakeven visibility.

Get alerted when GH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Guardant Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GH

BlackRock, Inc.
$1.1B11,553,759 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$539.3M5,837,992 sh
VANGUARD CAPITAL MANAGEMENT LLC
$519.5M5,624,180 sh
Invesco Ltd.
$456.9M4,946,469 sh
GOLDMAN SACHS GROUP INC
$409.7M4,435,839 sh
TWO SIGMA INVESTMENTS, LP
$390.7M4,229,531 sh
FMR LLC
$380.2M4,116,081 sh
BAILLIE GIFFORD & CO
$356.5M3,859,046 sh
GEODE CAPITAL MANAGEMENT, LLC
$324.2M3,508,883 sh
Capital International Investors
$321.6M3,481,318 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	11,553,759
VANGUARD PORTFOLIO MANAGEMENT LLC	$539.3M	5,837,992
VANGUARD CAPITAL MANAGEMENT LLC	$519.5M	5,624,180
Invesco Ltd.	$456.9M	4,946,469
GOLDMAN SACHS GROUP INC	$409.7M	4,435,839
TWO SIGMA INVESTMENTS, LP	$390.7M	4,229,531
FMR LLC	$380.2M	4,116,081
BAILLIE GIFFORD & CO	$356.5M	3,859,046
GEODE CAPITAL MANAGEMENT, LLC	$324.2M	3,508,883
Capital International Investors	$321.6M	3,481,318

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GH on your watchlist

Track score changes the day Guardant Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GH a good stock to buy?

13F Pro's AI-powered analysis of Guardant Health, Inc. (GH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GH are available on the GH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Guardant Health, Inc.'s investment landscape.